Fig. 3
From: Review targeted drug delivery systems for norcantharidin in cancer therapy
The antitumor efficacy of NCTD, DMCA-Zn1 NPs and DMCA-Zn2 NPs for liver cancer in vivo. a The administration process of NCTD, DMCA-Zn1 NPs and DMCA-Zn2 NPs for Hep3B xenograft mice (n = 5). b The tumor efficacy of NCTD, DMCA-Zn1 NPs and DMCA-Zn2 NPs in Hep3B xenograft mice (n = 5) The tumor volumes were normalized to their initial sizes. Statistical significance: *p < 0.05, **p < 0.01 and ***p < 0.001. c The photographs of Hep3B xenograft mice treated with NCTD, DMCA-Zn1 NPs and DMCA-Zn2 NPs at 0, 6, 21, and 24 days. d The body weights of Hep3B xenograft mice during cancer treatment (n = 5). Values are mean ± SD, n = 5. ***Values are highly significant difference (p < 0.001). Reproduced with permission from reference [87]. Copyright 2022, Royal Society of Chemistry